for its correlation with and low bias in estimating daytime ambulatory BP (2-4). Trial qualification requirements summarized in our paper are correct but incomplete: systolic blood pressure (SBP) Ն160 mm Hg according to the BpTRU protocol was mandatory, along with 2 office cuff readings of SBP Ն160 mm Hg within 3 months of enrollment. Resistant hypertension was assured by requiring 24-h average ambulatory SBP Ն135 mm Hg and Ն1 month of Ն3 concomitant antihypertensive medications.
Device Therapy in Heart Failure Patients With Chronic Kidney Disease
We read with great interest the recent article in the Journal by Cannizzaro et al. (1) . The researchers provided a great overview of various trials in the use of implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy in patients with chronic kidney disease (CKD) and congestive heart failure (CHF).
According to the U.S. Renal Data System, more than half a million people were enrolled in the Medicare-funded end-stage renal disease program at the end of 2008. Cardiovascular deaths are the leading cause of mortality in patients with CKD. This increased risk of cardiovascular and all-cause mortality is apparent even in the early stages of the disease (2) .
There is a dearth of randomized controlled trials investigating the use of therapies in CHF and CKD (3). ICDs are underutilized in patients with CKD and CHF. We had the opportunity to carry out a post hoc analysis addressing the impact of renal dysfunction on survival in a secondary prevention population from the AVID (Antiarrhythmics Versus Implantable Defibrillators) trial (4,5).
